N'-(3,4-dichlorophenylhydrazinocarbonyl)acetic acid methyl ester | 1158813-61-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N'-(3,4-dichlorophenylhydrazinocarbonyl)acetic acid methyl ester
• 英文别名: Methyl 3-(2-(3,4-dichlorophenyl)hydrazinyl)-3-oxopropanoate；methyl 3-[2-(3,4-dichlorophenyl)hydrazinyl]-3-oxopropanoate
• CAS: 1158813-61-6
• 化学式: C₁₀H₁₀Cl₂N₂O₃
• 分子量: 277.107
• InChiKey: DCTGXGHCWVNUER-UHFFFAOYSA-N

物化性质

• 沸点：
  352.4±42.0 °C(Predicted)
• 密度：
  1.445±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N'-(3,4-dichlorophenylhydrazinocarbonyl)acetic acid methyl ester 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以1.5 g的产率得到1-(3,4-dichlorophenyl)pyrazolidine-3,5-dione
  参考文献：
  名称：

  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

  摘要：

  Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure-activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.062
• 作为产物：
  描述：

  丙二酸甲酯酰氯 、 (3,4-二氯苯基)肼 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以4.3 g的产率得到N'-(3,4-dichlorophenylhydrazinocarbonyl)acetic acid methyl ester
  参考文献：
  名称：

  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors

  摘要：

  Individuals with Down syndrome (DS) suffer from mental retardation. Overexpression and the resulting increased specific activity of Dyrk1A kinase located on chromosome 21 cause a learning and memory deficit in Dyrk1A transgenic mice. To search for therapeutic agents with Dyrk1A inhibition activity, previously we obtained HCD160 as a new hit compound for Dyrk1A inhibition. In the present study, we synthesized 34 HCD160 derivatives to investigate the quantitative structure-activity relationship (QSAR). This analysis could provide important information for novel drug discovery for treatment of DS related learning and memory deficits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.062

文献信息

• MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR
  申请人：Kyoto University

  公开号：EP3124024A1

  公开（公告）日：2017-02-01

  A pharmaceutical composition for neovascular diseases, a pharmaceutical composition for inhibiting an angiogenic growth factor, and use of these pharmaceutical compositions are provided. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a low molecular weight compound that is able to suppress the expression of the VEGF gene in cells or to reduce the production of VEGF protein from cells. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a compound expressed by the following formula (I) or a prodrug thereof or pharmaceutically acceptable salts thereof

  本文提供了一种治疗新生血管疾病的药物组合物、一种抑制血管生成生长因子的药物组合物以及这些药物组合物的用途。 在一个或多个实施方案中，一种药物组合物含有一种低分子量化合物作为活性成分，该化合物能够抑制细胞中血管内皮生长因子基因的表达或减少细胞中血管内皮生长因子蛋白的产生。在一个或多个实施方案中，药物组合物含有下式(I)表示的化合物或其原药或其药学上可接受的盐作为活性成分